WAYNE, Pa. and SYDNEY, Sept. 22 /PRNewswire/ — Molecular
Detection Inc. (MDI), a company developing Detect-Ready™
assays designed to increase the speed and accuracy of infectious
disease diagnosis, and Integrated Sciences Pty. Ltd. today
announced that they have entered into an exclusive distribution
agreement for MDI’s Detect-Ready MRSA assay in Australia. The
Detect-Ready MRSA assay offers healthcare providers a
high-performance MRSA screening test with an unmatched combination
of accuracy, speed, flexibility and cost-effectiveness.
Integrated Sciences recently launched the Detect-Ready MRSA
assay into the Australian market.
“This latest agreement continues our strategy of partnering our
Detect-Ready MRSA assay with leading distributors worldwide,” said
Todd Wallach, CEO of MDI. “The Detect-Ready MRSA assay offers
important advantages, and we believe that Integrated Sciences’
focus on top-quality customer service and expert technical support,
along with its national reach, will help our Detect-Ready assay
achieve strong acceptance in the growing Australian market for MRSA
screening.”
Drug-resistant, potentially deadly MRSA (methicillin-resistant
Staphylococcus aureus) infections are a growing problem in
healthcare facilities around the world. The Detect-Ready MRSA
kit is a qualitative real-time PCR (rt-PCR) in vitro
diagnostic test for the direct detection of MRSA nasal colonization
to aid in the prevention and control of MRSA infections in
hospitals and other healthcare settings. The proprietary
technology in the Detect-Ready kits provides a unique differential
diagnosis engine that produces highly accurate results, minimizing
the false positives and false negatives experienced with other MRSA
screening kits. Samples for testing are simple to obtain
using nasal swabs and the assay’s ready-to-use pre-mixed reagents
require only the addition of patient sample to run the test, which
provides r
‘/>”/>
